At a glance
- LillyDirect self-pay vials are the cheapest brand path: $299 (2.5 mg), $399 (5 mg), $449 (7.5 to 15 mg) as of Dec 2025.
- Retail brand Zepbound and Mounjaro pens run about $1,000 to $1,300 cash per 28-day box in 2026, list ~$1,086 to $1,135.
- Licensed 503A compounded tirzepatide via telehealth starts near $139 per month. The old 503B shortage window closed March 19, 2025.
- SURMOUNT-1 (Jastreboff 2022, PMID 35658024): 22.5% mean weight loss at 15 mg over 72 weeks vs 2.4% placebo.
- SURMOUNT-5 (Aronne 2025, PMID 40353578) head-to-head: tirzepatide 20.2% vs semaglutide 13.7% at 72 weeks. Do not chase cheap gray-market vials.
Ask "how much is tirzepatide without insurance" and you will get five numbers back, all real, all for the same molecule. The pen at CVS is roughly $1,189. A LillyDirect single-dose vial is $299 to $449. A licensed 503A telehealth compounded vial starts near $139. And a semaglutide (not tirzepatide) vial from an unlicensed offshore site is $80 and probably contains 8 percent of what it claims. This guide prices every legal path per 28 days and per active milligram, and shows exactly where the search results skip the important asterisk.
This is the 2026 tirzepatide-generic-and-compounded per-mg cost accounting. For the Zepbound brand-pen-only walkthrough see our cheapest Zepbound path guide. For the specific Hers-branded flow see our Hers tirzepatide cost breakdown.
The one-sentence answer
If you are willing to draw from a vial with a syringe and buy through Lilly's direct-to-consumer channel, tirzepatide (as Zepbound) costs $299 to $449 per 28 days in 2026, depending on dose. If you insist on the auto-injector pen, the cash price at a retail pharmacy runs about $1,000 to $1,300 per box.
Every other number you see is a variation on one of those two floors, with a telehealth wrapper, a compounded copy, or a coupon on top.
LillyDirect self-pay vials: the current brand floor
Eli Lilly announced lower pricing on Zepbound single-dose vials on December 1, 2025. As of 2026 the LillyDirect self-pay tier is:
| Dose | LillyDirect vial (28-day) | Per active mg |
|---|---|---|
| 2.5 mg weekly | $299 | ~$29.90 |
| 5 mg weekly | $399 | ~$19.95 |
| 7.5 mg weekly | $449 | ~$14.97 |
| 10 mg weekly | $449 | ~$11.23 |
| 12.5 mg weekly | $449 | ~$8.98 |
| 15 mg weekly | $449 | ~$7.48 |
Per-mg cost drops sharply as you titrate up. At 15 mg weekly the effective rate is under $8 per milligram of active drug, the cheapest brand-price tier in the US market.
Three real conditions apply.
Vials are not pens. The LillyDirect $299 to $449 tier ships single-dose glass vials, not the KwikPen auto-injector. You draw the dose with a fresh insulin syringe (usually 27 to 31 gauge, 5/16 inch), which costs $10 to $20 per month at a pharmacy. Our reconstitution calculator covers the arithmetic if you ever handle compounded lyophilized product; a LillyDirect vial ships pre-reconstituted at the labeled dose so there is no math, just a draw.
Refill cadence gates the price on the top tier. The 7.5 to 15 mg vials at $449 flat require a refill within 45 days. Miss the window and the standard self-pay price ratchets to about $599, $699, $849, and $1,049 respectively for a first-time or lapsed order.
LillyDirect Self-Pay is a Lilly-run channel. Prescription and eligibility are handled by the LillyDirect fulfillment pathway using a partnered US-licensed prescriber network for patients who do not already have a script. You still see a clinician, asynchronously, before shipment.
Retail brand pens: the ceiling most people see first
The retail cash price for a 28-day box of four Zepbound or Mounjaro auto-injector pens sits well above the LillyDirect vial floor in 2026.
| Brand | List (WAC) | Common retail cash range | Notes |
|---|---|---|---|
| Zepbound (obesity) | ~$1,086 | ~$1,000 to $1,300 | Coupon programs bring commercial-insured patients to $25 to $650 with prior auth. Cash uninsured pays the full sticker. |
| Mounjaro (T2D) | ~$1,135 | ~$1,100 to $1,300 | No Lilly cash discount program for uninsured; commercial-insured savings card runs to $25 with cap. |
CVS runs Mounjaro in a $1,159 to $1,229 corridor, Walgreens near list. Costco and Sam's Club cash-pay members typically save $150 to $200 per fill.
Two things to notice. First, the retail brand-pen price is about 2.4x the LillyDirect 15 mg vial price for the same molecule at the same dose. Second, the Zepbound and Mounjaro pens contain identical tirzepatide at identical doses, so choosing between them is a matter of which indication your prescriber writes for.
503A compounded tirzepatide via telehealth: the current lower tier
Compounded tirzepatide is not the same regulatory category as brand Zepbound. It is a patient-specific preparation, made by a US-licensed compounding pharmacy from bulk API under a valid prescription. The 503A pathway remained legal in 2026 for patients whose prescriber determines a commercially available product is clinically unsuitable (dose, allergy to an inactive, or specific formulation need such as microdose or B12-blend).
The prior 503B outsourcing pathway closed on March 19, 2025, after the FDA declared the tirzepatide shortage resolved on December 19, 2024, a decision upheld by the courts. That killed the bulk-copy telehealth model. Any operator still selling generic "compounded tirzepatide" as a direct commercial substitute in 2026 is either running the 503A patient-specific route legitimately, or operating in a gray zone that is now the subject of active Lilly litigation against Mochi, Fella, Henry Meds, Willow, and others.
Prices we track from vetted 503A partners in 2026:
| Provider | 12-month plan starting price | What ships |
|---|---|---|
| Bodybuilding Health+ | From $139 per month | Compounded semaglutide primary; tirzepatide on eligibility |
| Gala Health | From $149 per month microdose | Compounded tirzepatide microdose, in-app progress tracker |
| TelosRx | From $49 per month microdose | Compounded tirzepatide microdose, oral/needle-free options |
| Yucca Health | From $206 per month (6-mo plan) | Compounded semaglutide, not tirzepatide |
| Medvi | From $199 per month | Compounded tirzepatide options |
For a canonical list of vetted 503A operators the site tracks, our compounded tirzepatide hub is the source of truth. Our live GLP-1 cheapest hub publishes the current monthly price watch across brand and compounded paths.
Warning: "Compounded tirzepatide" from an offshore website or a non-503A operator is not the same product. A 2024 JMIR analysis (Kompella et al. 2024, PMC11582493) of unlicensed semaglutide products sold online found measured purity of 7.70 to 14.37 percent against a labeled 99 percent, with detectable endotoxin in every sample. A legitimate 503A path uses a US-licensed pharmacy, a patient-specific prescription from a US-licensed prescriber in your state, and USP 797 sterile-compounding standards. Cheap is not the same as legal, and legal is not the same as safe.
Every legal 2026 path, side by side
Here is the whole picture on one grid, ranked cheapest to most expensive at the 5 mg dose:
| Path | 28-day cost at 5 mg | Format | The catch |
|---|---|---|---|
| TelosRx microdose (12-mo) | ~$49 | Compounded vial or oral | Microdose tier, not a commercial-dose equivalent |
| Bodybuilding Health+ (12-mo) | ~$139 | Compounded vial | Program eligibility; semaglutide primary |
| Gala Health microdose (12-mo) | ~$149 | Compounded vial | Microdose formulation only |
| LillyDirect vial | $399 | Brand single-dose vial | Draws with own syringe |
| Retail Mounjaro at Costco | ~$900 to $950 | Brand pen | Membership required |
| Retail Zepbound cash (GoodRx) | ~$1,000 to $1,086 | Brand pen | Coupon depends on pharmacy |
| Retail Mounjaro cash (CVS) | ~$1,159 to $1,229 | Brand pen | National corridor |
| Hers Zepbound program | $1,899 plus $149/mo | Brand pen | Membership stacking; brand only path |
The 25x span between the top and bottom row is real, and every row is legal. What separates them is molecule format (microdose compounded vs commercial dose), regulatory pathway (brand vs 503A), and service wrapper.
What tirzepatide actually delivers at the dose
Whatever you pay per month, you are paying for the same dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, and the clinical case is unusually clean for the obesity category.
SURMOUNT-1 (Jastreboff et al. 2022, PMID 35658024) randomized 2,539 adults with obesity (or overweight plus a comorbidity, without type 2 diabetes) to tirzepatide 5 mg, 10 mg, 15 mg, or placebo weekly for 72 weeks. Mean weight reduction reached 22.5 percent at the 15 mg dose, 21.4 percent at 10 mg, 16.0 percent at 5 mg, versus 2.4 percent on placebo. About 91 percent of tirzepatide participants lost at least 5 percent of body weight.
SURMOUNT-2 (Garvey et al. 2023, PMID 37385274) confirmed the effect in patients with type 2 diabetes: 938 adults, 15.7 percent mean weight reduction at 15 mg versus 3.3 percent placebo across 72 weeks.
SURMOUNT-5 (Aronne et al. 2025, PMID 40353578) is the head-to-head that made every downstream telehealth pitch legible. A 751-patient, 72-week open-label randomized trial in adults with obesity without diabetes produced 20.2 percent mean weight reduction on maximum-tolerated tirzepatide versus 13.7 percent on maximum-tolerated semaglutide, with a waist-circumference gap of 18.4 cm versus 13.0 cm. GI-related discontinuation was lower on tirzepatide (2.7 percent vs 5.6 percent). Our tirzepatide vs semaglutide 2026 guide covers the trial in more depth.
SURMOUNT-4 (Aronne et al. 2024, PMID 38078870) is the trial to read before you sign a long payment plan. After a 36-week lead-in on maximum-tolerated tirzepatide (mean 20.9 percent weight loss), participants were randomized 1:1 to continued tirzepatide or placebo. The continued arm lost another 5.5 percent over 52 weeks. The placebo-switched arm regained 14.0 percent of body weight over the same period. Stopping the drug is not a taper to a lower steady state, it is a re-entry to the pre-drug setpoint.
The takeaway for cost planning: whatever monthly price you commit to, expect to sit on it for the medium term or line up a maintenance path with your prescriber before stopping. That reality alone often decides brand pen vs compounded vial.
Per-mg accounting, so the numbers land
That 25x monthly-price span between compounded microdose and brand pen is not really a per-milligram gap. It is a mixture of dose, formulation category, and service.
At the 5 mg commercial-equivalent dose (once weekly, 28-day supply = 20 mg total active drug):
| Path | 28-day cost | Active mg | $ per mg |
|---|---|---|---|
| LillyDirect vial | $399 | 20 | $19.95 |
| Costco cash pen | ~$925 | 20 | ~$46.25 |
| CVS cash pen | ~$1,189 | 20 | ~$59.45 |
| Hers Zepbound | $1,899 | 20 | ~$94.95 |
| Bodybuilding Health+ compounded | ~$139 | 20 (typical) | ~$6.95 |
Compounded at $139 for a 5 mg-equivalent week is roughly $7 per milligram, one third of LillyDirect and one thirteenth of Hers. The value question is not whether it is "cheaper," which is obvious, but whether the specific 503A operator is legitimate, uses a US-licensed pharmacy, ships tested product, and has a prescriber who will taper you appropriately. Our best tirzepatide compounding pharmacy guide is the vendor-selection walkthrough for that decision.
Bottom line: The lowest legitimate per-mg price for real tirzepatide in 2026 is $7 to $8 (compounded 5 mg-equivalent through a vetted 503A telehealth partner). The highest is roughly $95 per mg (Hers brand pen). The brand pen buys convenience, familiarity, and a straight regulatory pathway. Nothing else.
The traps that make the wrong number look good
Three patterns keep repeating in the "how much is tirzepatide without insurance" search results.
Trap 1: an unlicensed offshore vendor selling "research-only" semaglutide for $80. The 2024 JMIR analysis measured that market at 7.70 to 14.37 percent purity with detectable endotoxin, meaning either a placebo dose or something you never want in a sterile injection. Tirzepatide is not commonly counterfeited yet at that scale precisely because Lilly holds active US patents to 2036 and enforces them, so the offshore semaglutide market is what a searcher usually stumbles into after typing a tirzepatide query. That market sits outside the 503A regulatory pathway entirely and rarely delivers the molecule at the labeled dose. Our lab-tests library documents what a legitimate third-party COA actually looks like.
Trap 2: a "compounded tirzepatide $99" ad from a non-503A operator. The 503B shortage window closed March 19, 2025, and the 503A route requires a patient-specific reason (dose, allergy, format). An operator offering commercial-equivalent tirzepatide at deep discount to any customer without patient-specific medical justification is either misrepresenting the pathway or exposed to active Lilly litigation. Our compounded tirzepatide legal access guide covers what a compliant program looks like today.
Trap 3: a $25 coupon that requires commercial insurance. The Zepbound and Mounjaro copay savings programs cap at $25 for eligible commercial-insured patients with prior authorization, and are worthless for the cash-pay uninsured buyer typing "without insurance" into a search bar. Read the eligibility fine print before treating a coupon headline as a price.
Decision matrix: pick the row that matches you
| Your situation | The path that costs least legally |
|---|---|
| Comfortable with a vial and syringe, want brand | LillyDirect self-pay ($299 to $449) |
| Insist on a pen and can absorb the surcharge | Costco or Sam's Club retail (~$900 to $950) |
| Insist on a pen and are not near a warehouse club | Zepbound retail cash + GoodRx (~$1,000 to $1,086) |
| Open to 503A compounded microdose | TelosRx ( |
| Prescriber will not approve tirzepatide, semaglutide is fine | Yucca Health ( |
| Already on Hers or Hims and want a cheaper same-drug path | LillyDirect vial + a new prescriber, or 503A telehealth transfer (see switching guide) |
| Uninsured with low income, need brand at $0 | Lilly Cares Foundation Patient Assistance Program (income-tested) |
If you are also weighing whether tirzepatide vs semaglutide is the right molecule for you, the SURMOUNT-5 head-to-head above is the anchor, and our tirzepatide vs semaglutide 2026 guide walks through the trial design and the trade-offs. If your total spend matters more than the specific molecule, our retatrutide cost breakdown covers where the next-generation Lilly triagonist is likely to price when it launches.
Frequently asked cost questions
Does the LillyDirect $299 to $449 price require insurance? No. It is a cash-pay tier that specifically exists for uninsured or under-insured patients. You do need a valid US prescription.
Can I use HSA or FSA to pay for LillyDirect or compounded tirzepatide? Usually yes, if the pharmacy accepts HSA cards or provides an itemized receipt. Confirm with your plan administrator.
Is compounded tirzepatide the same molecule as Zepbound? Chemically the active molecule is the same tirzepatide. Legally it is a different regulatory category (503A patient-specific compounded vs FDA-approved biologic). The main practical differences are the vial-and-syringe format (no auto-injector), potential B12 or other add-in blends, and reliance on the compounding pharmacy's own quality control rather than Lilly's manufacturing process.
How much syringe and needle do I need per month for a LillyDirect vial? One insulin syringe per weekly dose (four per month), plus one alcohol swab per injection and a small sharps container. Under $20 per month total from any pharmacy.
Is Mounjaro cheaper than Zepbound without insurance? No. List and cash prices sit within about 5 percent of each other, and both are the same molecule. Insurance coverage and formulary status differ; cash pricing does not meaningfully.
Can I get tirzepatide through Medicare or Medicaid? Medicare Part D generally does not cover obesity medications, so Zepbound is usually not covered; Mounjaro may be covered for type 2 diabetes. Medicaid coverage is state-by-state. See our Medicare GLP-1 bridge hub for the current 2026 map.
What to do next
When cost is the deciding factor, the LillyDirect vial at $299 to $449 is the cheapest brand path, and a vetted 503A telehealth partner is the cheapest legal path overall. Start with our live GLP-1 cheapest hub for the monthly price watch, and read the Bodybuilding Health+ review if the compounded telehealth lane fits your situation.
Buyers who insist on the pen format should pick a retail pharmacy with a warehouse-club rate and layer a manufacturer savings card only if they carry commercial insurance. If you are already inside a brand-only telehealth program like Hers, our Hers tirzepatide cost breakdown shows exactly how much of the sticker is drug and how much is wrapper.
Whatever path you choose, expect to hold on the drug for the medium term. SURMOUNT-4 is unusually clear about what happens when it stops.
Research and educational purposes only. This article prices commercial and compounded GLP-1 programs and cites published clinical trials. It is not medical advice. Tirzepatide carries contraindications (personal or family history of medullary thyroid carcinoma, MEN 2, active pancreatitis, severe GI disease, pregnancy) and requires prescriber evaluation, monitoring, and appropriate titration. Compounded medications are not FDA-approved. Always work with a US-licensed clinician for any prescription, dose change, or discontinuation.
